title: HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
abstract: Many solid tumors consist of large regions of poorly perfused cells, resulting in areas of low oxygen (hypoxia) throughout the cell mass. Cells subjected to hypoxia turn on a complex set of responses that alter their metabolism, rebalance their survival mechanisms, increase their invasive capacity, and stimulate angiogenesis. This allows them to at least temporarily escape the nutrient starvation and cell death resulting from this hostile environment. Accordingly, the hypoxic regions of tumors are often sources of the most aggressive and therapy-resistant cells, and therefore those cells that drive tumorigenesis. The hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs) are enzymes that are functionally inactivated in hypoxia, as they use both oxygen and alpha-ketoglutarate as substrates to hydroxylate target prolyl residues. Although HIF1alpha, the most highly characterized PHD target, orchestrates many of the cellular responses to hypoxia observed in tumors, PHDs themselves have previously been shown to regulate some hypoxia responses, including apoptosis, in a HIF-independent mechanism. We have previously shown that PHDs can be reactivated under hypoxia and that this results in a metabolic defect, both in vitro and in vivo. This led us to investigate whether chronic reactivation of these enzymes may inhibit tumor progression. We show here that esterified alpha-ketoglutarate given daily will induce apoptosis and inhibit tumor growth, in vivo. The effects are independent of HIF1alpha but dependent on the presence of PHD3. These data suggest that PHD3 may be a valid target in vivo for anti-tumor therapy.
authors.affiliation: Cancer Research UK, The Beatson Institute for Cancer Research, Glasgow, UK.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Tennant
authors.forename: Eyal
authors.initials: E
authors.lastname: Gottlieb
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D049308:Dioxygenases / Q000378:metabolism*; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D007656:Ketoglutaric Acids / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology
chemical_list: D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007656:Ketoglutaric Acids; D049308:Dioxygenases; C488894:EGLN3 protein, human; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases
references.citation: Mol Cell Biol. 2008 May;28(10):3386-400
references.pmid: 18332118
references.citation: Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
references.pmid: 7539918
references.citation: EMBO J. 2003 Aug 15;22(16):4082-90
references.pmid: 12912907
references.citation: N Engl J Med. 2008 Dec 18;359(25):2685-92
references.pmid: 19092153
references.citation: Oncogene. 2002 Jan 24;21(5):836-43
references.pmid: 11850811
references.citation: Cell. 2001 Oct 5;107(1):43-54
references.pmid: 11595184
references.citation: Gastroenterology. 2010 Mar;138(3):1143-54.e1-2
references.pmid: 19818783
references.citation: Biol Chem. 2004 Mar-Apr;385(3-4):223-30
references.pmid: 15134335
references.citation: Science. 2001 Nov 9;294(5545):1337-40
references.pmid: 11598268
references.citation: J Biol Chem. 1996 Jul 26;271(30):17771-8
references.pmid: 8663540
references.citation: Nat Genet. 2008 Feb;40(2):170-80
references.pmid: 18176562
references.citation: J Physiol. 2004 Oct 1;560(Pt 1):21-6
references.pmid: 15319416
references.citation: Cancer Res. 2003 Dec 15;63(24):8777-83
references.pmid: 14695194
references.citation: Br J Cancer. 2009 Oct 6;101(7):1168-74
references.pmid: 19724277
references.citation: Gene. 2001 Sep 5;275(1):125-32
references.pmid: 11574160
references.citation: Cancer Cell. 2009 Jun 2;15(6):527-38
references.pmid: 19477431
references.citation: Cancer Cell. 2005 Jan;7(1):77-85
references.pmid: 15652751
references.citation: Cancer Res. 2003 Apr 15;63(8):1764-8
references.pmid: 12702559
references.citation: J Biol Chem. 2003 Aug 15;278(33):30772-80
references.pmid: 12788921
references.citation: Nat Rev Drug Discov. 2009 Feb;8(2):139-52
references.pmid: 19165233
references.citation: Nat Rev Mol Cell Biol. 2008 Apr;9(4):285-96
references.pmid: 18285802
references.citation: Oncogene. 2009 Nov 12;28(45):4009-21
references.pmid: 19718054
references.citation: Nat Rev Cancer. 2002 Jan;2(1):38-47
references.pmid: 11902584
references.citation: Biochem Pharmacol. 2007 Feb 1;73(3):450-7
references.pmid: 17101119
references.citation: Nat Rev Mol Cell Biol. 2004 May;5(5):343-54
references.pmid: 15122348
references.citation: Mol Oncol. 2008 Jun;2(1):41-53
references.pmid: 19383328
references.citation: Mol Biol Cell. 2007 Nov;18(11):4528-42
references.pmid: 17804822
references.citation: Exp Cell Res. 2005 May 15;306(1):274-84
references.pmid: 15878351
references.citation: Cancer Cell. 2009 Nov 6;16(5):413-24
references.pmid: 19878873
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5
references.pmid: 11504942
references.citation: Mol Cell Biol. 2007 Feb;27(3):912-25
references.pmid: 17101781
references.citation: Expert Rev Mol Med. 2009 Aug 27;11:e26
references.pmid: 19709449
references.citation: Cell. 2009 Mar 6;136(5):839-851
references.pmid: 19217150
references.citation: Eur J Haematol. 2010 Jan 1;84(1):47-51
references.pmid: 19737309
references.citation: Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9
references.pmid: 9223322
references.citation: Cancer Cell. 2005 Aug;8(2):155-67
references.pmid: 16098468
references.citation: Nat Rev Cancer. 2008 Dec;8(12):967-75
references.pmid: 18987634
references.citation: Am J Pathol. 2000 Aug;157(2):411-21
references.pmid: 10934146
references.citation: Sci Signal. 2009 Jul 07;2(78):ra33
references.pmid: 19584355
references.citation: Genes Dev. 2008 Apr 1;22(7):884-93
references.pmid: 18334619